Wednesday, September 30, 2009

4:00-5:00 p.m.

Registration

5:00 p.m.

6:00 p.m.

7:00 p.m.

Welcome ceremony by Co-Chairs of Symposium: Enrico Garaci and Allan L. Goldstein

Keynote Address:  Guido Rasi

“Regulatory Aspects of Combination Therapies”

Cocktails

Thursday, October 1, 2009

8:00-8:45 a.m.

Registration and Breakfast

8:45-12:10 a.m.

Plenary Session 1: Thymosins: structure design, isoforms, multifunctionality, receptors, cancer

Chairs: Ewald Hannappel & Marie-France Carlier

Speakers:
Luigina Romani (Perugia, IT):  “Thymosin alpha1:  regulator of regulators?”

Claudia Matteucci (Rome, IT):  “Thymosin alpha 1 and viruses”

Ewald Hannappel (Erlangen, DE):  “Thymosin beta 4”

Marie-France Carlier (Gif sur Yvette, France)

Kevin Freeman & Bruce Zetter (Boston, MA): “A novel Thymosin beta 4 complex on human endothelial cells”

Czeslaw S. Cierniewski (Lodz, PL):Thymosin beta4 regulates migration of colon cancer cells by a pathway involving interaction with Ku80

Ruggero DeMaria, (Rome, IT):  “Role of Thymosin beta 4 in Colon Carcinoma”

Jo Caers & Karen Vanderkerken (Brussel, BE):  “Decreased Thymosin beta 4 Expression Results in Poor Prognosis and Decreased Survival in Multiple Myeloma”

12:10 p.m.

Lunch – 1 hour 45 minutes

2:00 p.m. -6:00 p.m.

Plenary Session 2: Cardiovascular Protection, Neuroplasticity, Stem Cells, Wound healing, Inflammation, and Angiogenesis

Chairs: Hynda Kleinman & Deepak Srivastava

Speakers:
Hynda Kleinman (Bethesda, MD)-“Thymosin beta 4 + Stem Cell Maturation”

Deepak Srivastava (San Francisco, CA):  Thymosin beta 4 Regulation of Cardiac Repair

Paul Riley (London, UK):  “Thymosin beta 4 induces epicardium derived neovascularization and myocardial regeneration in the injured adult heart”

Christian Kupatt (Munich, DE):  Thymosin beta 4 in ischemic syndromes:  From cell to protein to gene therapy

3:15 p.m.

Coffee Break

3:45 p.m.- 5:05 p.m.

Daniela Merlo (Rome, IT):  “Down-regulation of Thymosin beta 4 in neural progenitor grafts promotes spinal cord regeneration”

Dan Morris (Detroit, MI):  “Thymosin beta 4 improves neurological function outcome in a new model of embolic stroke”

Gabe Sosne (Detroit, MI):  “Thymosin beta 4 and Corneal Wound Healing:  Visions of the Future”.

H.Paul Ehrlich (Hershey, PA)

     Title: TBA

5:05 p.m. – 6:05 p.m.

Poster Session

Evening Awards Banquet: Scientific Awardees & Lifetime Humanitarian Awardees

Friday, October 2, 2009

9:00 a.m.-1:00 p.m.

Plenary Session 3: Clinical Applications of Thymosin alpha 1, IRX-2, and Interferon
Chairs: Enrico Garaci & Roberto Camerini
Speakers:
Enrico Garaci (Rome, Italy

      Title: TBA

Israel Rios and Cynthia Tuthill (San Francisco, CA):  “Thymosin alpha 1:  Past clinical experience and future promise”.

Kenneth Sherman (Cincinnati, OH):  Thymosin and Hepatitis C U.S. Trials

Alessia Ciancio and Mario Rizzetto (Turin, IT):  “Thymosin alpha 1 in the treatment of hepatitis B and C”

Pietro Andreone (Bologna, IT):  “Modification of immune responses inducted by retreatment with Thymosin alpha 1 plus Pegasys and Ribavirin in patients with HIV infection previously non-responders to Pegalyated-IFN and Ribavirin”

Virginia Ferraresi (Rome, IT):  “A Large European Phase II Randomized Study of Thymosin alpha 1, interferon Alpha, or Both, in Combination with Dacarbazine in Patients with Malignant Melanoma”

Andrea Velardi (Perugia, IT):  “Thymosin alpha 1 in CMV positive patients after bone marrow transplantation”

Paul Naylor and John Hadden (Cold Spring Harbor, NY):  “IRX-2 and Thymosin alpha 1 Combination Therapy”

Filippo Belardelli (Rome, IT):  “Novel strategies for enhancing the efficacy of immunotherapy in cancer patients”

11:55 a.m. - 1:00 p.m.

Lunch

1:00 p.m.-3:00 p.m.

Plenary Session 4: Clinical Applications of Thymosin beta 4
Chairs: Giorgio Guarnera & David Crockford

Speakers:
David Crockford (Bethesda, MD):  Thymosin beta 4 – An Overview of its Structure, Function,  Biolgical Properties, and Potential Clinical Applications

Giorgio Guarnera (Rome, IT):  A Phase II Safety and Efficacy trial of a Thymosin beta 4 Gel Product (RGN-137) in the Treatment of Patients With Venous Stasis Ulcers Secondary to Chronic Venous Insufficiency

Steven P. Dunn & Gabe Sosne (Detroit, MI):  Thymosin beta 4 in the Treatment of Chronic Non-Healing Neutrophic Corneal Defects

Jo-David Fine (Nashville, TN):  A Phase II Blinded Assessment of Wound Healing Properties of Thymosin beta 4 Gel Product (RGN-137) in the Treatment of Patients with Dystrophic and Junctional Epidermolysis  Bullosa

Dennis Ruff (San Antonio, TX):  The Clinical Safety of Thymosin beta 4 Parenteral Solution (RGN-352) Assessed in a Phase I Study of Healthy Volunteers

Deepak Srivastava (San Francisco, CA):  A Phase II Clinical Trial Evaluating the Safety and Efficacy of Thymosin beta 4 (RGN-352) in Patients with ST Elevation Myocardial Infarction

3:00 p.m.

Adjournment